ASIA unversity:Item 310904400/86933
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 90437/105768 (86%)
造訪人次 : 10940495      線上人數 : 656
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋


    題名: Signaling cross-talk in the resistance to HER family receptor targeted therapy.
    作者: Yamaguchi, H;Yamaguchi, H.;Chang, S-S.;Chang, S-S.;Hsu, J.L.;Hsu, J.L.;洪明奇*
    貢獻者: 生物科技學系
    日期: 2014
    上傳時間: 2014-11-07 14:53:06 (UTC+8)
    摘要: Epidermal growth factor receptor (EGFR) and human EGFR 2 (HER2) have an important role in the initiation and progression of various types of cancer. Inhibitors targeting these receptor tyrosine kinases are some of the most successful targeted anticancer drugs widely used for cancer treatment; however, cancer cells have mechanisms of intrinsic and acquired drug resistance that pose as major obstacles in drug efficacy. Extensive studies from both clinical and laboratory research have identified several molecular mechanisms underlying resistance. Among them is the role of signaling cross-talk between the EGFR/HER2 and other signaling pathways. In this review, we focus particularly on this signaling cross-talk at the receptor, mediator and effector levels, and further discuss alternative approaches to overcome resistance. In addition to well-recognized signaling cross-talk involved in the resistance, we also introduce the cross-talk between EGFR/HER2-mediated pathways and pathways triggered by other types of receptors, including those of the Notch, Wnt and TNFR/IKK/NF-κB pathways, and discuss the potential role of targeting this cross-talk to sensitize cells to EGFR/HER2 inhibitors.
    關聯: ONCOGENE;33(9):1073-81.
    顯示於類別:[生物科技學系] 期刊論文


    檔案 大小格式瀏覽次數


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋